ClinicalTrials.gg
RecruitingNCT07222683RESTOREUpdated Oct 30, 2025

The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease

An observational study in Chronic Kidney Disease, Kidney Transplant and Coronary Microvascular Dysfunction (CMD), sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Brigham and Women's Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital — 4 open to participants now, 5 under way, none of them phase 3. Renal Insufficiency, Chronic · Brigham and Women's Hospital.

Started
2023
the only one that year
Observational
7 of 21
1 open now
Registered
20th of 21
by date

Among the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital, this one is the only one that started in 2023, is one of 7 observational ones, and was the 20th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

People with chronic kidney disease (CKD) often experience faster aging of the heart and blood vessels, which raises the risk of heart problems beyond traditional factors like high blood pressure or cholesterol. One early sign is reduced blood flow in the tiny vessels that supply the heart, measured by a positron emission tomography (PET) scan using a marker called myocardial flow reserve (MFR). In CKD, ongoing inflammation and abnormal blood vessel growth can damage these small vessels, leading to heart stiffness and weaker heart function.

A kidney transplant offers a unique chance to study how better kidney function and reduced inflammation affect heart health. The observational RESTORE study ("Impact of Renal Transplant on Coronary Microvascular Function in Patients with Advanced CKD") will measure heart blood flow and function before and after transplant.

The study will test whether:

  1. Inflammation and abnormal vessel growth are linked to poor heart blood flow and heart function in CKD.
  2. Kidney transplant improves heart blood flow and function.
  3. Lower inflammation after transplant leads to better heart health.

By understanding how kidney disease and inflammation affect the heart-and how transplant may reverse these effects-this research could help guide future treatments to better protect heart health in patients with CKD.

03

Conditions studied

  • Chronic Kidney Disease
  • Kidney Transplant
  • Coronary Microvascular Dysfunction (CMD)
  • Inflammation

Keywords

  • chronic kidney disease
  • coronary microvascular dysfunction
  • kidney transplant
  • cardiovascular inflammation
  • dysregulated angiogenesis
  • coronary artery disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with advanced kidney disease who are candidates for renal transplant will be included in the RESTORE study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Renal transplant candidate on the waitlist
  • Age greater or equal to 45 years, or if 18-44 years of age on dialysis for 5 years or more

Exclusion criteria

Exclusion Criteria:

  • (LVEF) \< 40%
  • History of coronary artery bypass grafting (CABG)
  • History of heart transplant
  • Patients who undergo revascularization as a result of pre-transplant cardiac PET
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Transplant Arm

    Patients followed before and after transplant

  • Waitlist Control Arm

    Patients followed before transplant while on the waitlist

06

What researchers measure

Primary outcomes

  1. Stress Myocardial Blood Flow (MBF)

    Myocardial blood flow with hyperemic stress measured on PET myocardial perfusion imaging

    Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  2. Myocardial Flow Reserve (MFR)

    Ratio of stress and rest myocardial blood flow assessed by PET

    Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  3. Left ventricular global longitudinal strain (GLS, %)

    Left ventricular global longitudinal strain measured on echocardiography

    Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  4. Left ventricular mitral inflow velocity to mitral annular early diastolic relaxation velocity ration (E/E')

    E/E' measured by echocardiography

    Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  5. Interleukin-6 (IL-6) levels

    IL-6 levels measured via proteomics assays

    Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  6. Vascular Endothelial Growth Factor A (VEGF-A)

    VEGF-A measured by proteomic assay

    Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  7. Angiopoeitin-1 (ANGPT1) Levels

    ANGPT1 levels measured by proteomic assay

    Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  8. Angiopoeitin-2 (ANGPT2) Levels

    ANGPT2 levels measured by proteomics

    Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

Secondary outcomes

  1. Left ventricular ejection fraction (LVEF)

    LVEF by echocardiography

    Time frame: 1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  2. High sensitivity c-reactive protein (hs-CRP)

    hs-CRP measured by blood assay

    Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

  3. High-sensitivity Troponin

    High-sensitivity troponin by blood assay

    Time frame: 1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All longitudinal human subjects data described in outcomes measures will be shared in a deidentified form. Both summarized data and individual will be shared via ClinicalTrials.gov and BioLINCC. Cardiovascular imaging data including PET and echocardiography will be shared as calculated parameters after expert interpretation from the raw images. The raw images will not be shared in a data depository, due to very large file-size, and the need for specialized software and expertise to interpret the imaging data. However, raw images may be available in a deidentified form upon appropriate and relevant request with an appropriate data transfer agreement. The protocol, sample informed consent, sample surveys, and data dictionaries will be shared on a data repository.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Start Date: June 30, 2030 End Date: Indefinite ClinicalTrials.gov and BioLINCC will make decisions about how long to preserve the data, but no deposited data has been deleted up to now.

Access criteria: All summarized and completely deidentified data on ClinicalTrials.gov will be publicly accessible without restriction. Data and metadata on the data repository BioLINCC will be controlled by standard processes at BioLINCC, including requirement for being a registered user on BioLINCC, the submission of an online request form, IRB approval, a research material distribution agreement, and approval by the NHLBI Data Repository Program Officer

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jul 2030, 88 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 88 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Oct 30, 2025
StartActual
Mar 10, 2023
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2030
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222683
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), American Heart Association
Responsible party
Daniel Michael Huck, MD, MPH (Clinical Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Oct 30, 2025
Start date
Mar 10, 2023
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Oct 30, 2025

Study contacts

Daniel M Huck, MD, MPH
Contact
dhuck@bwh.harvard.edu
8573074000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion